MedTrace Logo

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

NCT02415595 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2018-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find at least one dose of BMS-955176 that will be safe, effective and tolerable for HIV-1 infected treatment naive adults.

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

DRUG

BMS-955176

HIV Maturation Inhibitor

DRUG

EFV

EFV

DRUG

TDF/FTC

TDF/FTC

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-12
Primary Completion
2016-05-26
Completion
2017-08-21

Countries

  • United States
  • Argentina
  • Canada
  • Chile
  • France
  • Germany
  • Italy
  • Mexico
  • Poland
  • South Africa
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02415595 on ClinicalTrials.gov